Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov

Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov

The recent development of dedicated prostate-specific membrane antigen (PSMA) targeted radioligands shows the potential to change and improve the diagnosis and therapy of prostate cancer. There is an increasing number of prospective trials to further establish these tracers in the clinical setting....

Full description

Bibliographic Details
Main Authors: Claus Zippel, Sarah C. Ronski, Sabine Bohnet-Joschko, Frederik L. Giesel, Klaus Kopka
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Pharmaceuticals
Subjects:
prostate cancer
psma tracer
registry data analysis
clinicaltrials.gov
theranostics
Online Access:https://www.mdpi.com/1424-8247/13/1/12

Internet

https://www.mdpi.com/1424-8247/13/1/12

Similar Items